Greenwich LifeSciences, Inc. (GLSI)
Oxford Ledge is still expanding full research coverage of GLSI. A live quote, fundamentals, and analysis are available in the app; the SEC-sourced material below is what we currently have indexed here.
Business summary
A biopharmaceutical company developing GLSI-100, an immunotherapy combining GP2 peptide and GM-CSF, to prevent breast cancer recurrence in a Phase III trial.
SEC filings
- 10-Q Quarterly financial report (unaudited) 2026-06-04
- 10-K Annual financial report with audited statements 2026-06-01
- 8-K Shareholder vote results 2025-12-18
- 10-Q Quarterly financial report (unaudited) 2025-11-14
- DEF 14A Proxy statement for shareholder vote 2025-11-03
Source: SEC EDGAR.
Insider activity
5 recent insider (SEC Form 4) filings on record for GLSI. View the transactions in the terminal.
Source: SEC EDGAR (Form 4).
- Open GLSI in the Oxford Ledge terminal — live quote, chart, and analysis in the app.
- Browse the covered-stock index
- Learn to analyze stocks yourself
The material above is drawn from public SEC EDGAR filings and is provided for educational purposes, not as investment advice. Live pricing and fundamentals are available in the terminal.